Manufacturing will take place at DSM Biologics plant in Brisbane, Australia
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM has signed an agreement with Tunitas Therapeutics of San Francisco, US to provide process development activities for a protein allergy drug being developed by Tunitas' Therapeutics.
Under the deal, DSM will develop production processes for the drug candidate, an Fc-fusion protein for the treatment of asthma and other allergic diseases.
Financial terms have not been disclosed.
The aim is to transfer production to DSM Biologics' recently opened manufacturing facility in Brisbane, Australia in collaboration with the Tunitas subsidiary, Tunitas Therapeutics Australia, which was established earlier this year in Melbourne.
Manja Bouman, President of DSM Biologics, said: 'It is an honour to support the development of Tunitas' promising drug candidate from our facilities in Groningen and Australia.
'We are impressed with the potential of this product and the health benefit to treat the millions of patients whose asthma is poorly-controlled on their current therapeutic regimens.'